Published on 1 May 2024 on GuruFocus.com via Yahoo Finance
TG Therapeutics Inc (TGTX) Surpasses Revenue Estimates in Q1 2024, Despite Widening Net Loss
Total Revenue: Reported $63.5 million in Q1 2024, surpassing estimates of $54.58 million.Net Loss: Recorded at $10.7 million for Q1 2024, significantly below the estimated net loss of $4.13 million.Earnings Per Share: Actual EPS of -$0.07, fell short of the estimated -$0.04.Product Revenue Growth: BRIUMVI U.S. net product revenue reached $50.5 million, indicating over 25% growth quarter over quarter.R&D Expenses: Increased to $32.7 million in Q1 2024 from $15.9 million in the same period last year, driven by development costs and licensing expenses.SG&A Expenses: Rose to $34.6 million due to scale-up activities for BRIUMVI's commercial launch.Cash Position: Ended the quarter with $209.8 million in cash, cash equivalents, and investment securities.
Warning! GuruFocus has detected 6 Warning Signs with TGTX.